Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
INCY
INCY
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
INCY News
Mixed Close for US Stocks as Retail Sales Stagnate
5d ago
NASDAQ.COM
US Retail Sales Weakness Impacts Markets
5d ago
NASDAQ.COM
Incyte Corporation Q4 2025 Earnings Call Highlights
5d ago
seekingalpha
Analysis of Significant Stock Movements Among Companies
5d ago
CNBC
Incyte Reports Q4 Results Below Expectations, Issues Weak 2026 Guidance
5d ago
seekingalpha
US Stocks Edge Up as Retail Sales Weaken
5d ago
NASDAQ.COM
Incyte (INCY) Q4 2025 Earnings Call Transcript
5d ago
NASDAQ.COM
Incyte Reports Q4 Earnings with Revenue Beat but EPS Miss
5d ago
seekingalpha
Key Earnings Reports and Economic Outlook This Week
Feb 08 2026
CNBC
Key Focus Areas This Week: Jobs, Consumer Prices, Coca-Cola, CVS, Ford, McDonald's, and More
Feb 08 2026
Barron's
U.S. Jobs and Inflation Data Set for Release
Feb 06 2026
CNBC
Wall Street Analysts Adjust Ratings
Feb 05 2026
Benzinga
Prelude Therapeutics Receives FDA Clearance for Blood Cancer Trial
Feb 03 2026
seekingalpha
Incyte's Cancer Therapy Zynyz Receives EMA Endorsement for New Indication
Jan 30 2026
seekingalpha
Incyte Receives Positive EMA Opinion for Zynyz in SCAC Treatment
Jan 30 2026
Businesswire
Zynyz® Receives Positive Opinion for SCAC Treatment in Europe
Jan 30 2026
Newsfilter
Show More News
